Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab

By  

Oncology, Vol. 93, Iss. 1, 2017-05 ,pp. : 51-61

Karger

Access to resources Recommend Favorite

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 555-559

Karger

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite

Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

By Campone Mario   Beck J. Thaddeus   Gnant Michael   Neven Patrick   Pritchard Kathleen I.   Bachelot Thomas   Provencher Louise   Rugo Hope S.   Piccart Martine   Hortobagyi Gabriel N.   Nunzi Martina   Heng Daniel Y.C.   Baselga José   Komorowski Anna   Noguchi Shinzaburo   Horiguchi Jun   Bennett Lee   Ziemiecki Ryan   Zhang Jie   Cahana Ayelet   Taran Tetiana   Sahmoud Tarek   Burris Howard A.  

Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. : 1463-1473

Informa Healthcare

Access to resources Recommend Favorite

Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 116, Iss. 8, 2017-12 ,pp. : 1021-1028

John Wiley & Sons Inc

Access to resources Recommend Favorite